Prioritization and Organ Distribution for Liver Transplantation

JAMA: The Journal of the American Medical Association

Volumn 271, Issue 2, 1994, Pages 140-143

  Bronsther, Oscar ^a   Fung, John J ^a   Izakis, Andreas ^a   Van Thiel, David ^a   Starzl, Thomas E ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIARY CIRRHOSIS; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; LIVER TRANSPLANTATION; ORGAN DONOR; POLICY; QUALITY OF LIFE; REVIEW; RISK FACTOR; SCLEROSING CHOLANGITIS;

EID: 0028144253     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1994.03510260072031     Document Type: Article

References (15)

1. Gaston RS, Ayres I, Dooley LG, Diethelm AG. Racial equity in renal transplantation: the disparate impact of HLA-based allocation. JAMA. 1993; 270:1352-1356.
2. Delmonico FL, Jenkins RL, Freeman R, et al. The high-risk liver allograft recipient: should allocation policy consider outcome? Arch Surg. 1992; 127:579-584.
3. Markus B, Dickson ER, Grambsch P, et al. Efficacy of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med. 1989;320: 1709-1713.
4. Dickson ER, Grambsch PM, Flening TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology. 1989;10:1-7.
5. National Institutes of Health Consensus Development Conference on Liver Transplantation. Hepatology 1984;4(suppl):1S-110S.
6. Starzl TE, Iwatsuki S, Van Thiel DH, et al. Evolution of liver transplantation. Hepatology. 1982; 2:614-636.
7. Abu-Elmagd K, Malinchoc M, Dickson ER, et al. Efficacy of liver transplantation in patients with primary sclerosing cholangitis. Surg Gynecol Obstet. 1993;177:335-344.
8. Dickson ER, Murtaugh PA, Grambsch PM, et al. Primary sclerosing cholangitis: refinement and validation of survival model. Gastroenterology. 1992; 103:1893-1901.
9. Muto P, Freeman RB, Haug CE, Lu A, Rohrer RJ. Liver transplant candidate stratification systems: implications for third-party payors and organ allocation. Transplantation. In press.
10. Van Thiel D, Wright H, Carroll P, et al. FK 506: a treatment for autoimmune chronic active hepatitis: results of an open label preliminary trial. Am J Gastroenterol. In press.
11. Henderson JM, Gilmore GT, Hooks MA, et al. Selective shunt in the management of variceal bleeding in the era of liver transplantation. Ann Surg. 1992;216:248-255.
12. Starzl TE, Gordon RD, Tzakis A, et al. Equitable allocation of extrarenal organs: with special reference to the liver. Transplant Proc. 1988;20 (suppl 1):5131-5138.
13. Kalayoglu M, Sollinger HW, Stratta RJ, et al. Extended preservation of the liver for clinical transplantation. Lancet. 1988;1:617-619.
14. Todo S, Nery J, Yanaga K, Podesta L, Gordon RD, Starzl TE. Extended preservation of human liver grafts with UW solution. JAMA. 1989;261: 711-714.
15. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramanan R, Jain A. FK 506 for human liver, kidney and pancreas transplantation. Lancet. 1989; 2:1000-1004.